Developer docs
API playgroundTry for free, no card

Search company profiles

OPTIC

Full company profile

uuid0000mm6

Namestring
OPTIC
Legal namestring
OPTIC, INC.
Websiteurl
bioptic.io
Company typeenum
Private
Founded yearint
2021
Descriptiontext

BIOPTIC (Optic Inc.) is a San Francisco-based, AI-native drug discovery company founded in 2021 that has built a unified platform combining three proprietary scientific AI models — B1 (a SMILES-based RoBERTa transformer for ligand-based virtual screening), B2 (a Flamingo-inspired sequence-based hit identification model), and B3 (a few-shot ADME prediction module built on Gemini) — with an autonomous Bioptic Agent for multilingual drug asset scouting. The platform screens ultra-large chemical libraries (40 billion+ compounds) in under 2.5 minutes with 100% recall at an estimated $5 per screen, and is validated through peer-reviewed publications in the Journal of Chemical Information and Modeling (LRRK2/Parkinson's, 14 confirmed binders, best Kd = 110 nM) and Cell Chemical Biology (Miro1/Friedreich's Ataxia, 62 novel compounds from a 3.2B library). BIOPTIC also advances its own internal and co-owned drug pipeline, including OPT-LR42 (Parkinson's/LRRK2), OPT-TN65 (Obesity/TNIK), and OPT-FL95 (Solid Tumors/VEGFR3), and contributes community infrastructure such as the PLUMBER benchmark (1.8M data points) released on Polaris.

The company serves pharmaceutical and biotech companies, biotech consultancies, corporate venture arms, BD&L teams, and academic institutions. Key partners include Vindur Tx ($17.5M cancer collaboration), Oncobox (co-developed VEGFR3 program), eMolecules (20M+ compound library integration), Mechanica (white-label venture creation), and Stanford University (Cell Chemical Biology collaboration). The technology has earned two gold medals at major AI competitions — CAFA 5 Protein Function Prediction (2023) and the BELKA Challenge at NeurIPS 2024 — and an AAAI 2026 award for the agentic due diligence paper; on the proprietary drug asset scouting benchmark, Bioptic Agent reaches 79.7% F1, materially ahead of Claude Opus 4.6 (56.2%), Gemini 3 Pro (50.6%), and GPT-5.2 Pro (46.6%).

BIOPTIC operates a hybrid revenue model combining SaaS subscription access with usage-based screening, fixed-sum collaboration deals, and white-label/OEM licensing for biotech consultancies. The company is entirely bootstrapped with no external venture capital and has reached $19.9M ARR with a $59.7M valuation. Distribution combines direct enterprise field sales, a self-serve pipeline platform (app.bioptic.io), integration partnerships, and white-label channels, while marketing relies heavily on peer-reviewed publications, conference presence (BIO, JPM Healthcare, NeurIPS, ASCO, SDDS), and industry association membership (Alliance for AI in Healthcare).

Short descriptiontext

BIOPTIC is an AI-native drug discovery company combining proprietary screening models (B1, B2, B3) with an autonomous drug asset scouting agent that screens 40B+ compounds in minutes. It serves pharma, biotech, BD&L teams, and academic institutions via subscription, collaboration, and white-label licensing models.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, molecular virtual screening, ADME prediction software, drug asset scouting, pharma competitive intelligence
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Pharmaceutical Preparations2834
Product category
AI Drug Discovery Platform
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1SaaS Platform Access (Subscription + Usage)
TypeSubscription Recurring
Description

AI drug discovery platform provided as a service. Customers pay for platform access and usage of screening capabilities. Revenue appears to be subscription-based with usage components, as evidenced by recurring billing language in terms of service.

bioptic.io
2Collaboration Deals
TypeSubscription Recurring
Description

Fixed-sum collaboration payments for specific drug discovery programs. Example: $17.5M collaboration with Vindur Tx for cancer treatment development. These are milestone-based deals rather than recurring SaaS.

bioptic.io
3Platform Licensing
TypeLicensing Royalties
Description

White-label model allowing biotech consultancies to compete under their own brand. Partners like Mechanica use BIOPTIC's capabilities to power AI-driven venture creation.

getlatka.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Pricing details3 tiers
1Enterprise SaaS with usage-based screening
ModelSubscriptionBilling cadenceMonthly
Notes

Estimated ~$5 per screen for 40B compound screening. Full enterprise pricing is quote-based. Terms of service indicate recurring billing (monthly) with auto-renewal.

bioptic.io
2Self-serve pipeline platform access
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Pipeline platform (app.bioptic.io) provides self-service access. Specific pricing not publicly disclosed.

bioptic.io
3White-label/Partner licensing
ModelOtherBilling cadenceMulti-year contract
Notes

Biotech consultancies can white-label the platform. Pricing negotiated per partnership.

bioptic.io
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

OPTIC (operating as BIOPTIC) sells an AI-native drug discovery platform combining three proprietary models — B1 (ligand-based ultra-high-throughput virtual screening), B2 (sequence-based hit identification), and B3 (ADME predictions) — along with an autonomous Bioptic Agent for drug asset scouting across global sources. The platform screens 40B+ compound libraries in minutes using SMILES-based transformers and graph neural networks, and supports both enterprise pharma collaborations and self-serve access for researchers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 40B compound screen completed in 2.5 minutes with 100% recall at ~$5 estimated cost
+4 more records
Product overview1 text field

OPTIC (operates as BIOPTIC) is an AI-native drug discovery company built around a unified platform combining three core scientific AI models — B1 (ligand-based virtual screening), B2 (sequence-based hit identification), and B3 (ADME predictions) — powered by a Bioptic Agent system for autonomous drug asset scouting. The platform screens ultra-large chemical libraries (40B+ compounds) in minutes using SMILES-based transformers and graph neural networks, enabling hit-to-lead conversion in weeks rather than years. OPTIC also develops its own internal and co-owned drug pipeline programs targeting LRRK2 (Parkinson's), TNIK (obesity), and VEGFR3 (solid tumors), and releases benchmarks and tools (PLUMBER) for the broader AI drug discovery community.

Product and service2 records
1BIOPTIC Platform
CategoryAI Drug Discovery Platform
Description

AI-native drug discovery platform that powers BIOPTIC's B1/B2/B3 models and the Bioptic Agent system, enabling scientists to screen billions of molecules in minutes, predict ADMET properties, and surface drug assets across global sources from target identification through lead optimization. Sold to enterprise pharma, biotech, and academic customers.

2BIOPTIC B1 — Ligand-Based Hit Identification
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-10
Description

Stanford-led study published in Cell Chemical Biology demonstrated BIOPTIC B1's ability to identify novel Miro1 ligands for Friedreich's Ataxia. BIOPTIC screened 3.2B molecules; Stanford synthesized and tested compounds in patient-derived neurons. Patent filed jointly. Second peer-reviewed publication validating BIOPTIC's platform.

Strategic tierKeyTypeStrategic or Co-development PartnerAnnounced on2025-06-06
Description

New partnership to power AI-driven venture creation. BIOPTIC's capabilities enable Mechanica to offer AI-powered drug discovery as part of their venture creation programs across multiple initiatives.

3Alliance for AI in Healthcare (AAIH)
Strategic tierIndustryTypeOthersAnnounced on2025-01-19
Description

Bioptic officially became member of AAIH alongside industry leaders like Roche, Google, Genentech. Membership provides access to global biotech/tel network, policy influence opportunities, and industry visibility. AAIH serves as unified voice for AI in healthcare advocating for standards and regulatory frameworks.

bioptic.io
4Vindur Tx
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-11-06
Description

$17.5M collaboration to accelerate development of novel cancer treatments. BIOPTIC provides proprietary AI platform to identify highly selective kinase inhibitors for 'undruggable' targets in difficult-to-treat cancers. Represents major validation of BIOPTIC's platform and business model.

bioptic.io
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-10-03
Description

Strategic partnership integrating eMolecules' 20M+ compound library into BIOPTIC's AI platform. Enables scientists to screen compounds and order hits directly through eMolecules' procurement system—streamlining the transition from virtual screening to laboratory validation. Addresses critical bottleneck in drug discovery workflow.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-08
Description

Partnership to advance targeted anti-cancer therapies. Oncobox used patient-derived multi-omic data to identify VEGFR-3 as promising target; BIOPTIC's AI discovered potent, selective inhibitors (IC50 = 420 nM). Combined approach accelerates precision oncology development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer in AI-driven small molecule drug discovery using convolutional neural networks on 3D molecular structures. Directly competes with BIOPTIC B1 in ligand-based virtual screening and serves similar pharma and biotech customers.

TypeDirect peer
Description

AI-driven drug discovery company combining generative chemistry, target discovery, and an internal pipeline. Overlaps with BIOPTIC's B1/B2/B3 platform and its strategy of developing both platform IP and proprietary programs.

TypeDirect peer
Description

AI-native drug discovery platform combining high-throughput biology with machine learning. Competes for the same enterprise pharma partnerships and BD&L-level attention, though its wet-lab-centric approach differs from BIOPTIC's purely in silico model.

TypeDirect peer
Description

Computational chemistry and physics-based drug discovery platform (LiveDesign, FEP+) used across pharma R&D. Overlaps with BIOPTIC's virtual screening and ADMET prediction offerings, though Schrödinger is more established and broader in scope.

TypeDirect peer
Description

AI-driven precision medicine and drug discovery company with both a platform and proprietary pipeline. Directly comparable as a full-stack AI drug discovery competitor targeting the same pharma enterprise customers.

6Isomorphic Labs
TypeBroad incumbent
Description

Alphabet/DeepMind-backed drug discovery company applying AlphaFold-era foundation models to pharma. Operates broadly in the same AI drug discovery category with much deeper resources and brand recognition.

TypeDirect peer
Description

AI drug discovery company combining knowledge graphs, target identification, and clinical development. Competes with BIOPTIC's Bioptic Agent for BD&L and competitive intelligence use cases within large pharma.

TypeEmerging player
Description

Early-stage AI drug discovery company using neural network-based molecular generation and physics-informed models. Comparable emerging peer pursuing novel chemistry for pharma partners.

TypeOthers
Description

AI research organization that co-released the PLUMBER benchmark with BIOPTIC and operates adjacent drug discovery infrastructure. Comparable as an ecosystem participant in AI-for-chemistry tooling.

TypeEmerging player
Description

AI protein engineering and biologics design company with a generative biology platform. Compares as a peer in the broader AI-for-biopharma tooling category, though focused on proteins rather than small molecules.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OPTIC

AI Drug Discovery Platformbioptic.io

BIOPTIC is an AI-native drug discovery company combining proprietary screening models (B1, B2, B3) with an autonomous drug asset scouting agent that screens 40B+ compounds in minutes. It serves pharma, biotech, BD&L teams, and academic institutions via subscription, collaboration, and white-label licensing models.

What OPTIC does

BIOPTIC (Optic Inc.) is a San Francisco-based, AI-native drug discovery company founded in 2021 that has built a unified platform combining three proprietary scientific AI models — B1 (a SMILES-based RoBERTa transformer for ligand-based virtual screening), B2 (a Flamingo-inspired sequence-based hit identification model), and B3 (a few-shot ADME prediction module built on Gemini) — with an autonomous Bioptic Agent for multilingual drug asset scouting. The platform screens ultra-large chemical libraries (40 billion+ compounds) in under 2.5 minutes with 100% recall at an estimated $5 per screen, and is validated through peer-reviewed publications in the Journal of Chemical Information and Modeling (LRRK2/Parkinson's, 14 confirmed binders, best Kd = 110 nM) and Cell Chemical Biology (Miro1/Friedreich's Ataxia, 62 novel compounds from a 3.2B library). BIOPTIC also advances its own internal and co-owned drug pipeline, including OPT-LR42 (Parkinson's/LRRK2), OPT-TN65 (Obesity/TNIK), and OPT-FL95 (Solid Tumors/VEGFR3), and contributes community infrastructure such as the PLUMBER benchmark (1.8M data points) released on Polaris.

The company serves pharmaceutical and biotech companies, biotech consultancies, corporate venture arms, BD&L teams, and academic institutions. Key partners include Vindur Tx ($17.5M cancer collaboration), Oncobox (co-developed VEGFR3 program), eMolecules (20M+ compound library integration), Mechanica (white-label venture creation), and Stanford University (Cell Chemical Biology collaboration). The technology has earned two gold medals at major AI competitions — CAFA 5 Protein Function Prediction (2023) and the BELKA Challenge at NeurIPS 2024 — and an AAAI 2026 award for the agentic due diligence paper; on the proprietary drug asset scouting benchmark, Bioptic Agent reaches 79.7% F1, materially ahead of Claude Opus 4.6 (56.2%), Gemini 3 Pro (50.6%), and GPT-5.2 Pro (46.6%).

BIOPTIC operates a hybrid revenue model combining SaaS subscription access with usage-based screening, fixed-sum collaboration deals, and white-label/OEM licensing for biotech consultancies. The company is entirely bootstrapped with no external venture capital and has reached $19.9M ARR with a $59.7M valuation. Distribution combines direct enterprise field sales, a self-serve pipeline platform (app.bioptic.io), integration partnerships, and white-label channels, while marketing relies heavily on peer-reviewed publications, conference presence (BIO, JPM Healthcare, NeurIPS, ASCO, SDDS), and industry association membership (Alliance for AI in Healthcare).

OPTIC firmographics

Firmographics
Name
OPTIC
Legal name
OPTIC, INC.
Website
https://bioptic.io
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
BIOPTIC is an AI-native drug discovery company combining proprietary screening models (B1, B2, B3) with an autonomous drug asset scouting agent that screens 40B+ compounds in minutes. It serves pharma, biotech, BD&L teams, and academic institutions via subscription, collaboration, and white-label licensing models.
Ownership category
akta.pro rank

OPTIC industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Molecular virtual screening
  • ADME prediction software
  • Drug asset scouting
  • Pharma competitive intelligence

Where OPTIC is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

OPTIC business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. SaaS Platform Access (Subscription + Usage): AI drug discovery platform provided as a service. Customers pay for platform access and usage of screening capabilities. Revenue appears to be subscription-based with usage components, as evidenced by recurring billing language in terms of service.
  2. Collaboration Deals: Fixed-sum collaboration payments for specific drug discovery programs. Example: $17.5M collaboration with Vindur Tx for cancer treatment development. These are milestone-based deals rather than recurring SaaS.
  3. Platform Licensing: White-label model allowing biotech consultancies to compete under their own brand. Partners like Mechanica use BIOPTIC's capabilities to power AI-driven venture creation.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyEnterprise SaaS with usage-based screening
Usage-basedPay-as-you-goSelf-serve pipeline platform access
OtherMulti-year contractWhite-label/Partner licensing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

OPTIC product offering

Product offering

Core offering

OPTIC (operating as BIOPTIC) sells an AI-native drug discovery platform combining three proprietary models — B1 (ligand-based ultra-high-throughput virtual screening), B2 (sequence-based hit identification), and B3 (ADME predictions) — along with an autonomous Bioptic Agent for drug asset scouting across global sources. The platform screens 40B+ compound libraries in minutes using SMILES-based transformers and graph neural networks, and supports both enterprise pharma collaborations and self-serve access for researchers.

Product overview

OPTIC (operates as BIOPTIC) is an AI-native drug discovery company built around a unified platform combining three core scientific AI models — B1 (ligand-based virtual screening), B2 (sequence-based hit identification), and B3 (ADME predictions) — powered by a Bioptic Agent system for autonomous drug asset scouting. The platform screens ultra-large chemical libraries (40B+ compounds) in minutes using SMILES-based transformers and graph neural networks, enabling hit-to-lead conversion in weeks rather than years. OPTIC also develops its own internal and co-owned drug pipeline programs targeting LRRK2 (Parkinson's), TNIK (obesity), and VEGFR3 (solid tumors), and releases benchmarks and tools (PLUMBER) for the broader AI drug discovery community.

Differentiator

Problem solved

Functional benefit

Products and services

  • BIOPTIC Platform AI-native drug discovery platform that powers BIOPTIC's B1/B2/B3 models and the Bioptic Agent system, enabling scientists to screen billions of molecules in minutes, predict ADMET properties, and surface drug assets across global sources from target identification through lead optimization. Sold to enterprise pharma, biotech, and academic customers.
  • BIOPTIC B1 — Ligand-Based Hit Identification

Quantifiable outcome

  • 40B compound screen completed in 2.5 minutes with 100% recall at ~$5 estimated cost
  • +4 more outcomes

Companies that use OPTIC

Customer profile

Named customers4 records

Segments6 records

Ideal customer profiles6 records

OPTIC technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability9 records

Feature5 records

OPTIC partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, key, industry and flagship.

  • Stanford University (Xinnan Wang Lab)coreStrategic or Co-development Partner · 10 June 2026Stanford-led study published in Cell Chemical Biology demonstrated BIOPTIC B1's ability to identify novel Miro1 ligands for Friedreich's Ataxia. BIOPTIC screened 3.2B molecules; Stanford synthesized and tested compounds in patient-derived neurons. Patent filed jointly. Second peer-reviewed publication validating BIOPTIC's platform.
  • MechanicakeyStrategic or Co-development Partner · 6 June 2025New partnership to power AI-driven venture creation. BIOPTIC's capabilities enable Mechanica to offer AI-powered drug discovery as part of their venture creation programs across multiple initiatives.
  • Alliance for AI in Healthcare (AAIH)industryOthers · 19 January 2025Bioptic officially became member of AAIH alongside industry leaders like Roche, Google, Genentech. Membership provides access to global biotech/tel network, policy influence opportunities, and industry visibility. AAIH serves as unified voice for AI in healthcare advocating for standards and regulatory frameworks.
  • Vindur TxflagshipStrategic or Co-development Partner · 6 November 2024$17.5M collaboration to accelerate development of novel cancer treatments. BIOPTIC provides proprietary AI platform to identify highly selective kinase inhibitors for 'undruggable' targets in difficult-to-treat cancers. Represents major validation of BIOPTIC's platform and business model.
  • eMoleculescoreTechnology or Integration · 3 October 2024Strategic partnership integrating eMolecules' 20M+ compound library into BIOPTIC's AI platform. Enables scientists to screen compounds and order hits directly through eMolecules' procurement system—streamlining the transition from virtual screening to laboratory validation. Addresses critical bottleneck in drug discovery workflow.
  • OncoboxcoreStrategic or Co-development Partner · 8 May 2024Partnership to advance targeted anti-cancer therapies. Oncobox used patient-derived multi-omic data to identify VEGFR-3 as promising target; BIOPTIC's AI discovered potent, selective inhibitors (IC50 = 420 nM). Combined approach accelerates precision oncology development.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

OPTIC competitors and assessment

Company assessment

Direct peers

  • Atomwise: Pioneer in AI-driven small molecule drug discovery using convolutional neural networks on 3D molecular structures. Directly competes with BIOPTIC B1 in ligand-based virtual screening and serves similar pharma and biotech customers.
  • Insilico Medicine: AI-driven drug discovery company combining generative chemistry, target discovery, and an internal pipeline. Overlaps with BIOPTIC's B1/B2/B3 platform and its strategy of developing both platform IP and proprietary programs.
  • Recursion Pharmaceuticals: AI-native drug discovery platform combining high-throughput biology with machine learning. Competes for the same enterprise pharma partnerships and BD&L-level attention, though its wet-lab-centric approach differs from BIOPTIC's purely in silico model.
  • Schrödinger: Computational chemistry and physics-based drug discovery platform (LiveDesign, FEP+) used across pharma R&D. Overlaps with BIOPTIC's virtual screening and ADMET prediction offerings, though Schrödinger is more established and broader in scope.
  • Exscientia: AI-driven precision medicine and drug discovery company with both a platform and proprietary pipeline. Directly comparable as a full-stack AI drug discovery competitor targeting the same pharma enterprise customers.
  • BenevolentAI: AI drug discovery company combining knowledge graphs, target identification, and clinical development. Competes with BIOPTIC's Bioptic Agent for BD&L and competitive intelligence use cases within large pharma.

Broad incumbents

  • Isomorphic Labs: Alphabet/DeepMind-backed drug discovery company applying AlphaFold-era foundation models to pharma. Operates broadly in the same AI drug discovery category with much deeper resources and brand recognition.

Emerging players

  • Iambic: Early-stage AI drug discovery company using neural network-based molecular generation and physics-informed models. Comparable emerging peer pursuing novel chemistry for pharma partners.
  • Cradle: AI protein engineering and biologics design company with a generative biology platform. Compares as a peer in the broader AI-for-biopharma tooling category, though focused on proteins rather than small molecules.

Others

  • Valence Labs: AI research organization that co-released the PLUMBER benchmark with BIOPTIC and operates adjacent drug discovery infrastructure. Comparable as an ecosystem participant in AI-for-chemistry tooling.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

OPTIC social profiles

Digital presence

OPTIC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OPTIC leadership team

Management profile

Number of profiles

Profiles7 records

OPTIC funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OPTIC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OPTIC

What does OPTIC do?

OPTIC (operating as BIOPTIC) sells an AI-native drug discovery platform combining three proprietary models — B1 (ligand-based ultra-high-throughput virtual screening), B2 (sequence-based hit identification), and B3 (ADME predictions) — along with an autonomous Bioptic Agent for drug asset scouting across global sources. The platform screens 40B+ compound libraries in minutes using SMILES-based transformers and graph neural networks, and supports both enterprise pharma collaborations and self-serve access for researchers.

Is OPTIC a public or private company?

OPTIC is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was OPTIC founded?

OPTIC was founded in 2021. It employs 11 to 50 people.

Where is OPTIC based?

OPTIC is headquartered in San Francisco, United States, in the North America region.

How does OPTIC make money?

Three revenue lines are on record. SaaS Platform Access (Subscription + Usage) is the primary driver. The others are collaboration Deals and platform Licensing.

Who are OPTIC's main competitors?

Direct peers on record are Atomwise, Insilico Medicine, Recursion Pharmaceuticals, Schrödinger, Exscientia and BenevolentAI. Isomorphic Labs is listed as a broad incumbent. Emerging players are Iambic and Cradle. Valence Labs is listed as an others.

Does OPTIC have an API?

No public API is recorded for OPTIC.

What industry is OPTIC in?

OPTIC's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals